Trials Open to Enrollment

AIDS Clinical Trials: New Trials Open to Enrollment http://www.actis.org/actinewl.html
5571095.0342.002
The following trials are just a sampling of the numerous trials which are currently open to enrollment.
For further information about the specific trials listed below, a complete listing of current trials open to
enrollment, and/or results from completed trials, call ACTIS at 1-800-874-2572 or 1-800-243-7012
(TTY) or e-mail ACTIS at actis(cdenac. org
Adults
t A Phase H Safety and Activity Study of Ritonavir in the Treatment of HIV Associated
Cutaneous Kaposi's Sarcoma. FDA 245C. Drug: Ritonavir.
The purpose of this Abbott Laboratories sponsored study is to evaluate the safety and
anti-Kaposi's sarcoma activity of ritonavir. For more information, view the Protocol Database
record.
Nt Q Pharmacokinetics Study of Intravenous Itraconazole Followed by Oral Dosing at 200 mg
Twice Daily in Patients with Advanced HIV Infection. FDA 254B. Drug: Itraconazole.
The purpose of this Janssen Research Foundation sponsored study is to demonstrate a dosage
regimen for intravenous itraconazole that produces a plasma concentration range comparable
to that obtained after currently used oral dosages of itraconazole oral solution; and to obtain
preliminary safety data in patients with advanced HIV disease. For more information, view the
Protocol Database record.
ME o Further Evaluation of Thalidomide'a Ability to Potentiate the Immune Response to HIV
Infected Patients. FDA 262A. Drug: Thalidomide.
The purpose of this LSU Lab Research Branch study is to determine if Thalidomide modulates
the production of mv-suppressor factors (MIP-1 alpha, MIP-1 beta, Rantes) and TH1 type
cytokines (IL-12 and INF-gamma) in HIV-infected patients and alters viral load. For more
information, view the Protocol Database record.
ItW S A Phase I/Ii Pilot Treatment Study Of CSF Penetration And Response To Ganciclovir
And Foscarnet In CMV Neurologic Disease. NIAID ACTG 305. Drugs: Foscarnet
sodium, Ganciclovir.
The purpose of this AIDS Clinical Trials Group study is to determine the safety and CSF
penetration of combined ganciclovir and foscamet treatment for presumed cytomegalovirus
encephalitis or radiculomyelopathy. For more information, view the Protocol Database
record.

NEdt L Effect of Vaccination on Turnover of Lamivudine (3TC) Sensitive and Resistant Virus
Populations IN HIV-1-Infected Individuals. NIAID ACTG 340. Drugs: Pneumococcal
vaccine polyvalent (23-valent), Influenza virus vaccine, Lamivudine.
The nnrnne of this AIR Cliniceal Trials Groiin strldv is to ascertain whether the oriain of

1 of 10

03/17/97 15:06:00